Skip to content

Role Of Bala Taila Nasya And Rasnadi Guggulu in Chronic Suppurative Otitis Media

Role Of bala Taila Nasya And Rasnadi Guggulu in Karnasrava (Chronic Suppurative Otitis Media)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/04/024829
Enrollment
30
Registered
2020-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H661- Chronic tubotympanic suppurative otitis media

Interventions

Intervention1: Bala Taila nasya and Rasnadi guggulu as oral medication: Bala Taila Nasya daily for 7days , after 3 days of interval procedure will be repeated for 7 days again , dose (6,8,10 drops in

Sponsors

Gurukul Campus
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 2.Patient having the symptoms of Vedna (earache), Karnasrava (ear discharge), perforation of TM, hearing impairment, and tenderness over mastoid antrum . 3.Clinically confirming the symptoms of (Karnasrava) Chronic suppurative otitis media by Otoscopic examination. 4.Tubotympanic type of chronic suppurative otitis media.

Exclusion criteria

Exclusion criteria: 1.Patient with complications of chronic suppurative otitis media. 2.Patient suffering from Diabetes Mellitus, HTN and Tuberculosis. 3.Pregnant and lactating females. 4.Patient below the age of 10 and above 60 years. 5.Patient not willing to participate in the study. 6.Atticoantral type of chronic suppurative otitis media.

Design outcomes

Primary

MeasureTime frame
To access the effect of therapy and medicine, objectively all signs and symptoms were given scoring depending upon their severity: 1.Cured: 80-100% relief in signs and symptoms 2.Markedly improved: 60-79% relief in signs and symptoms 3.Moderately improved: 40-59% relief in signs and symptoms 4.Mild improvement: 20-39% relief in signs and symptoms 5.No improvement: less than or equal to 19% relief in symptomsTimepoint: Assessment will be done on 1st, 7th and 17th day of trial and Follow up will be carried out after completion of trial on every 15 day for 1 month.

Secondary

MeasureTime frame
Exacerbation of signs and symptomsTimepoint: 47 Days (17 days for trial and Follow up for 01 month)

Countries

India

Contacts

Public ContactProf Dr R K Bishwal

Gurukul Campus, Uttarakhand Ayurveda university, Haridwar

drbishwal72@gmail.com9870649106

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026